Recordati acquista i diritti del farmaco Enjaymo e si rafforza nelle malattie rare. L’impatto su ricavi ed ebitda
Enjaymo è il farmaco per la malattia dell’agglutinina fredda. L’accordo con Sanofi prevede un pagamento iniziale di 825 milioni di dollari, con ricavi stimati fino a 300 milioni di euro annui e un imp ...
Recordati, maxi acquisizione da 1 miliardo nelle malattie rare
Recordati chiude la più grande acquisizione della sua storia. Il gruppo italiano ha comprato dal colosso francese Sanofi i ...
Borse europee in calo, petrolio continua a salire
Il Btp 10 anni sale al 3,54%. In serata i dettagli dell'asta Bot annuale di giovedì. Sulla vicenda Unicredit-Commerzbank il ...
Reuters3d
Recordati buys rights to rare immune disorder drug from Sanofi for $825 mln
Oct 4 (Reuters) - Italian pharma group Recordati (RECI.MI), opens new tab said on Friday it would buy from Sanofi (SASY.PA), opens new tab the global rights to a drug used to treat cold agglutinin ...
FiercePharma3d
In sustained rare disease push, Recordati lays out $825M upfront to acquire Sanofi's CAD drug Enjaymo
As Sanofi continues to clean out its medicine chest, Italy’s Recordati is getting in on the action. Recordati is floating $825 million upfront—plus another $250 million in potential commercial ...
Yahoo Finance3d
Recordati to acquire worldwide rights to Sanofi’s antibody Enjaymo
Recordati has reached an agreement with Sanofi for acquiring the worldwide rights to Enjaymo, the only approved treatment specifically targeting cold agglutinin disease (CAD), a rare B-cell ...
Business Insider3d
RECORDATI ANNOUNCES AGREEMENT TO ACQUIRE THE GLOBAL RIGHTS TO ENJAYMO®, STRENGTHENING ITS RARE DISEASES FRANCHISE
Milan, 4 th October 2024 – Recordati today announces an agreement with Sanofi to acquire the global rights to Enjaymo® (sutimlimab), a biologic which is the only approved targeted product for ...
AOL3d
Recordati buys rights to rare immune disorder drug from Sanofi for $825 million
(Reuters) -Italian pharma group Recordati said on Friday it would buy from Sanofi the global rights to a drug used to treat cold agglutinin disease (CAD), a rare autoimmune disorder, for $825 ...
Yahoo Finance4d
RECORDATI ANNOUNCES AGREEMENT TO ACQUIRE THE GLOBAL RIGHTS TO ENJAYMO®, STRENGTHENING ITS RARE DISEASES FRANCHISE
Subject to the closing date, Recordati expects minimal revenue contribution in 2024. The transaction is expected to be immediately accretive at the EBITDA level, with margin above the current Rare ...
Yahoo Finance3d
Recordati buys rights to rare immune disorder drug from Sanofi for $825 million
(Reuters) -Italian pharma group Recordati said on Friday it would buy from Sanofi the global rights to a drug used to treat cold agglutinin disease (CAD), a rare autoimmune disorder, for $825 million, ...